TRENDING :  Market Movers  |  Top 50   SPY (0.88%)    JNJ (0.03%)    TSLA (1.46%)    UGAZ (-14.63%)    RLGT (0%)    RDFN (0%)    OMER (3.24%)    NVDA (-0.26%)    NNDM (0.48%)    KOPN (2.18%)    HTZ (2.36%)    HTGM (8.47%)    GS (1.24%)    GNC (0.77%)    GDX (1.05%)    FB (-0.59%)    EWC (1.19%)    DSLV (-3.71%)    CI (-0.03%)    CARA (2.54%)    BUZ (0%)    BOIL (-9.11%)    BHC (1.63%)    AU (1.69%)    ASNA (-3.48%)

 MRK - Merck & Company

$74.50 (0.23%)

Next Earnings

2/1/2019

BMO



Analyst Rating

CompanyAnalyst NamePT ActionActionRatingTargetDate
CitigroupAndrew BaumRaisesMaintainsBuy$84.0011/01/18
CitigroupAndrew BaumRaisesMaintainsBuy$84.0010/31/18
SunTrust Robinson HumphreyEric FlemingRaisesMaintainsBuy$80.0010/29/18
BMO CapitalAlex ArfaeiLowersMaintainsOutperform$80.0010/26/18
BMO CapitalAlex ArfaeiRaisesMaintainsOutperform$82.0010/22/18
CitigroupAndrew BaumRaisesMaintainsBuy$79.0010/16/18
BarclaysGeoff MeachamRaisesMaintainsOverweight$78.0010/12/18
Credit SuisseVamil DivanRaisesMaintainsOutperform$81.0010/11/18
BarclaysGeoff MeachamRaisesMaintainsOverweight$75.0009/07/18
Morgan StanleyDavid RisingerRaisesMaintainsOverweight$74.0008/23/18
Bank of AmericaJason GerberryRaisesMaintainsBuy$74.0007/30/18
BMO CapitalAlex ArfaeiRaisesMaintainsOutperform$70.0004/26/18
Goldman SachsJami RubinUpgradesBuy$0.0004/23/18
Bank of AmericaJason GerberryRaisesMaintainsBuy$70.0004/18/18
Morgan StanleyDavid RisingerUpgradesOverweight$0.0004/17/18
BarclaysGeoff MeachamUpgradesOverweight$0.0004/05/18
Credit SuisseVamil DivanLowersMaintainsOutperform$65.0002/14/18
DZ BankUpgradesBuy$0.0002/13/18
Morgan StanleyDavid RisingerRaisesMaintainsEqual-Weight$63.0002/07/18
Leerink SwannSeamus FernandezLowersMaintainsMarket Perform$67.0002/06/18
Credit SuisseVamil DivanLowersMaintainsOutperform$66.0002/05/18
SunTrust Robinson HumphreyEric FlemingUpgradesBuy$0.0001/16/18

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $MRK

TRENDING ARTICLES



Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study

12/18/18
Eli Lilly amp Company s LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis PsA while also providing skin clearance in a head to head study comparing it with AbbVie Inc s ABBV blockbuster medicine Humira The primary endpoint of

Merck's Keytruda Gets EU Nod as Adjuvant Therapy for Melanoma

12/18/18
Merck amp Co Inc MRK announced that the European Commission has approved its anti PD 1 therapy Keytruda for the treatment of high risk stage III melanoma patients in the adjuvant setting The nod was based on favorable data from the pivotal phase III KEYNOTE 054 study The study

J&J Okays $5B Stock Buyback Plan, Stock Remains Stressed

12/18/18
Johnson amp Johnson JNJ said its board of directors has authorized a share buyback plan worth 5 billion and maintained its previously issued guidance for 2018 J amp J expects 2018 adjusted earnings per share in the range of 8 13 8 18while revenues are anticipated in the band of 81 81

Merck (MRK) Stock Moves -1.63%: What You Should Know

12/18/18
Merck MRK closed at 75 23 in the latest trading session marking a 1 63 move from the prior day This change was narrower than the S amp P 500 s daily loss of 2 08 Elsewhere the Dow lost 2 11 while the tech heavy Nasdaq lost 2 27 Prior to today s trading shares of the

Incyte (INCY) Collaborates with Innovent for 3 Candidates

12/17/18
Incyte INCY announced that it entered into a collaboration agreement with China based Innovent Biologics Inc Both the companies have entered into the agreement through their respective subsidiaries for the development of three clinical stage product candidates pemigatinib FGFR1 2

Merck to Acquire Europe's Antelliq Group for $2.4 Billion

12/17/18
Merck amp Co Inc MRK announced that it has reached a definitive agreement to acquire all the outstanding shares of French animal health company Antelliq Group for a reported 2 1 billion euros 2 38 billion in cash Merck will also bear Antelliq s debt of 1 15 billion euros 1 30

Lilly (LLY) to Acquire Pain Candidate From Private Biotech

12/17/18
Eli Lilly and Company LLY announced that it has entered into an agreement with Massachusetts based privately held Hydra Biosciences Inc The move will add the latter s pre clinical pain candidate to the company s portfolio and also strengthen its pain pipeline portfolio Following this

J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc

12/17/18
Johnson amp Johnson s JNJ stock was down more than 10 on Friday after Reuters reported that the pharma giant knew for decades that its baby powders contained asbestos J amp J has more than 11 000 cases pending related to its baby powders containing talc in the United States Most of

Better Buy: Eli Lilly and Company vs. Merck & Co.

12/17/18
Pharmaceutical heavyweights Merck amp Co Inc NYSE MRK and Eli Lilly and Company NYSE LLY are getting a lot of attention after outperforming the market by a mile in 2018 Both stocks have risen more than 30 this year but investors need to know which of these

Merck Announces Approval For KEYTRUDA In Adjuvant Setting In European Union

12/17/18
Merck Announces Approval For KEYTRUDA In Adjuvant Setting In European Union

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

12/14/18
The VanEck Vectors Pharmaceutical ETF PPH was launched on 12 20 2011 and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare Pharma segment of the equity market Retail and institutional investors increasingly turn to passively managed ETFs

5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019

12/14/18
The performance of the drug biotech space has been mixed so far this year The Zacks Large Cap Pharmaceuticals industry comprising some of the world s biggest drugmakers has gained 8 3 against the S amp P 500 Composite s decrease of 0 9 However the riskier Zacks Medical Biomedical

Merck To Buy Antelliq For EUR 2.1 Bln Plus Debt Of EUR 1.15 Bln

12/14/18
Merck To Buy Antelliq For EUR 2.1 Bln Plus Debt Of EUR 1.15 Bln

J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study

12/13/18
Johnson amp Johnson JNJ announced results from a head to head phase III ECLIPSE study which compared its psoriasis drug Tremfya guselkumab with Novartis NVS psoriasis drug Cosentyx secukinumab The study evaluated the efficacy of the first in class IL 23 inhibitor Tremfya

Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA

12/13/18
Mallinckrodt plc s MNK subsidiary SpecGx LLC reported that the FDA has issued a complete response letter CRL for its new drug application NDA seeking approval of opioid analgesic candidate MNK 812 The candidate is an abuse deterrent immediate release reformulation of commonly

Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug

12/13/18
Eli Lilly amp Company s LLY signed a collaboration agreement with Swiss biotech AC Immune SA ACIU to jointly develop tau aggregation inhibitors which have the potential to treat Alzheimer s disease AD and other neurodegenerative diseases Per the deal AC Immune will develop the

Merck & Company, Inc. (MRK) Ex-Dividend Date Scheduled for December 14, 2018

12/13/18
Merck amp Company Inc MRK will begin trading ex dividend on December 14 2018 A cash dividend payment of 0 55 per share is scheduled to be paid on January 08 2019 Shareholders who purchased MRK prior to the ex dividend date are eligible for the cash dividend payment This represents

Merck, Brazilian Non-profit Organization To Develop Dengue Vaccine

12/12/18
Merck, Brazilian Non-profit Organization To Develop Dengue Vaccine

XLRN On Watch, BPMC Makes An Imprint, Osteoporosis Drug Evenity Faces FDA Panel

12/03/18
XLRN On Watch, BPMC Makes An Imprint, Osteoporosis Drug Evenity Faces FDA Panel

Bayer To Cut 12,000 Jobs Worldwide

11/29/18
Bayer To Cut 12,000 Jobs Worldwide

Biotech Stocks Facing FDA Decision In December

11/26/18
Biotech Stocks Facing FDA Decision In December